Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can brain training help depressed young adults stop ruminating?

NCT ID NCT06219681

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether real-time fMRI neurofeedback could help young adults with major depression reduce repetitive negative thinking. Participants received either real or fake feedback while their brain activity was monitored. The trial was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
real-time fMRI neurofeedback
What this could lead to
If successful, this approach could point toward a non-drug therapy for reducing repetitive negative thinking in depression.
What could go wrong
The trial was terminated early, so results are limited. It was a small, early-stage study, and the intervention may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Young adults ages 18-35 * Participants who are able to give written informed consent prior to participation * Meeting DSM-5 diagnostic criteria for MDD who are currently depressed defined by the MINI * Participants who have RNT symptoms (Brooding subscale of Ruminative Response Scale: RRS-B ≥ 13) Exclusion Criteria: * Moderate to severe traumatic brain injury (\>30 min. loss of consciousness or \>24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits * Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke), pulmonary, endocrine, neurological diseases (e.g., Parkinson's disease), or gastrointestinal illness, as well as pain disorders * Current significant suicidal ideation or suicide attempt within the previous 12 months * Current psychosis * Schizophrenia or schizoaffective disorder * Substance use disorder within the previous 12 months, except for mild alcohol, cannabis, or tobacco use disorder defined as less than 4 symptoms of the criteria for substance use disorder according to the MINI * Current diagnosis of post-traumatic disorder (PTSD) defined by the MINI * Severe claustrophobia * Bodily implants of unsafe paramagnetic materials such as pacemakers and aneurysm clips * Pregnancy * Current regular use of cardiovascular medications with a direct vasomotor effect, namely beta- or alpha-beta-blockers, clonidine, and antianginal agents. * Current use of more than three psychotropic medications * Evidence of recreational drug use from a urine test * Commencement of psychotropic medication for depression and/or anxiety less than a month before the study enrollment * Commencement of psychological therapy less than a month before the study enrollment * Participants who have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder will be excluded * Participants who, on arrival to the study, have a temperature greater than 100.4°F will not be allowed to initiate the study * The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, major are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Laureate Institute for Brain Research

    Tulsa, Oklahoma, 74136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.